Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    144
    ...
ATC Name B/G Ingredients Dosage Form Price
L03AX03 BCG-MEDAC G BCG seed RIVM derived from seed 1173-P2 - 2x10? to 3x10? viable units Injectable powder for suspension+diluent 18,750,588 L.L
M01AE01 CAPTAIN G Ibuprofen - 100mg/5ml 100mg/5ml Suspension 335,321 L.L
N02AA01 CHLORHYDRATE DE MORPHINE RENAUDIN G Morphine HCl - 20mg/ml 20mg/ml Injectable solution 1,100,607 L.L
N03AX12 GABANET 400 G Gabapentin - 400mg 400mg Capsule 1,607,236 L.L
P02CF01 IVERMECTIN BENTA G Ivermectin - 6mg 6mg Tablet 470,985 L.L
R06AA52 HISTALIX G Diphenhydramine HCl - 14mg/5ml, Ammonium chloride - 135mg/5ml, Menthol - 1.1mg/5ml Syrup 384,339 L.L
J05AF10 HEPCAVIR 0.5 G Entecavir monohydrate - 0.5mg 0.5mg Tablet, film coated L.L
A10BA02 GLUCOCURE G Metformin - 850mg 850mg Tablet 217,575 L.L
B05XA03 CHLORURE DE SODIUM PROAMP G Sodium chloride - 0.9% 0.9% Injectable solution 705,517 L.L
C07AB03 ATENOLOL BIOGARAN G Atenolol - 50mg 50mg Tablet, scored 295,645 L.L
C09DA03 ARBITEN PLUS G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet 544,256 L.L
D11AX01 MINOXIDIL BAILLEUL G Minoxidil - 2% 2% Solution 2,839,539 L.L
G04CB01 FINASTERIDE BAILLEUL G Finasteride - 1mg 1mg Tablet, film coated 1,619,330 L.L
J01DD02 NEGACEF G Ceftazidime (pentahydrate) - 1g 1g Injectable dry powder for solution 4,421,242 L.L
J01MA12 LEFLUMAX G Levofloxacin (hemihydrate) - 750mg 750mg Tablet, film coated 1,006,538 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 2.5mg 2.5mg Tablet 57,802,039 L.L
L03AX03 SII-ONCO-BCG G Bacillus Calmette- Guerin Strain - 40mg/ml (1-8x10?CFU) 40mg/ml Injectable dry powder 6,987,981 L.L
M01AE01 DIMIDON G Ibuprofen - 20mg/ml 20mg/ml Suspension 483,783 L.L
N02AA01 MORPHINE MEDIS G Morphine HCl - 10mg/ml 10mg/ml Injectable solution 1,050,885 L.L
N03AX12 GABAPENTINE ARROW GENERIQUES G Gabapentin - 400mg 400mg Capsule 1,342,499 L.L
N05CM18 DEXMEDETOMIDINE EVER PHARMA G Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable concentrate for solution 9,340,433 L.L
P02DA01 TAENIASAN G Niclosamide - 500mg 500mg Tablet 94,709 L.L
R06AA52 MENTEX G Diphenhydramine HCl - 12.5mg/5ml, Dextrometorphan HBr - 15mg/5ml, Pseudoephedrine HCl - 30mg/5ml Syrup 323,866 L.L
V03AE02 FOSEAL-800 G Sevelamer HCl - 800mg 800mg Tablet, film coated 470,345 L.L
J05AF10 HEPCAVIR 1 G Entecavir monohydrate - 1mg 1mg Tablet, film coated L.L
A10BA02 GLYFORMIN G Metformin HCl - 850mg 850mg Tablet 391,058 L.L
A11GA01 VITAMIN C S.A.L.F. G Ascorbic acid (vit C) - 500mg/5ml 500mg/5ml Injectable solution 498,566 L.L
B05XA03 ISOTONIC SALINE G Sodium chloride - 0.9% 0.9% Injectable solution 188,772 L.L
C07AB03 ATONIUM G Atenolol - 50mg 50mg Tablet 239,588 L.L
C09DA03 CO-ANGINET G Valsartan - 160mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 544,256 L.L
    ...
    144
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026